CD6 (Cluster of Differentiation 6) is a surface glycoprotein of T cells and a subset of B cells, and belongs to the superfamily of scavenger receptor cysteine-rich (SRCR) glycoproteins. CD166, ALCAM and CD318 are ligands for CD6. CD6 interacts with its ligands and plays a key role in thymocyte development, T cell activation and immune responses. CD6 is structurally similar to CD5. CD6 and CD5 have been regarded as co-stimulatory receptors that amplify T-cell receptor (TCR)-dependent activation. CD6 is an important target for therapy against autoimmune diseases, such as Anti-CD6 monoclonal antibody (mAb)[1][2].
| 货号 | 产品名 | Cas | 产品描述 |
|---|---|---|---|
| PL06070 | Itolizumab | 1116433-11-4 | Itolizumab (Anti-Human CD6 Recombinant Antibody) 是一种人源化重组 抗 CD6 单克隆抗体 (MAb)，靶向 CD6 的细胞外 SRCR 远端结构域 1。Itolizumab 可减少 T 细胞增殖并抑制促炎细胞因子的产生，例如 INF-γ、TNFα 和 IL-6。Itolizumab 可用于银屑病、类风湿性关节炎 (RA)、COVID-19 的研究。 |
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
